Journal of Clinical Endocrinology & Metabolism, Vol 73, 596-603, Copyright © 1991 by Endocrine Society

ARTICLES

Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients

A Giwercman, H von der Maase, JG Berthelsen, M Rorth, A Bertelsen and NE Skakkebaek
University Department of Growth and Reproduction, Rigshospitalet, Copenhagen, Denmark.

Twenty men (median age, 31 yr) previously treated for unilateral testicular cancer received localized irradiation in a dose of 20 Gray in 10 fractions for carcinoma in situ of the remaining testis. Follow- up testicular biopsies performed 3 (n = 19) and 24 (n = 14) months after the treatment showed in all cases a Sertoli cell-only pattern. Hormonal evaluation was performed before as well as 3, 12, 24, and 36 months after radiation treatment. Endocrine parameters were followed for a median of 30 months (3-36 months). Baseline serum testosterone values decreased during the follow-up period from 13.3 +/- 6.0 to 10.8 +/- 6.4 nmol/L (mean +/- SD), although the decrease was not statistically significant (P = 0.06). Serum LH values increased during the first 3 months of follow-up from 10.4 +/- 5.4 to 15.6 +/- 7.3 IU/L (P less than 0.0001) and then remained unchanged. Significant decreases in GnRH- and hCG-stimulated testosterone levels also indicated an impairment of Leydig cell function. FSH levels increased (P less than 0.0001) during the first 3 months of follow-up from 21.8 +/- 11.1 to 33.2 +/- 13.2 IU/L. We conclude that localized irradiation of 20 Gray eradicated carcinoma in situ germ cells. Development of a second testicular cancer has until now been prevented. Leydig cell function was partially impaired by the radiation dose given.

This article has been cited by other articles:

				P. M. Petersen, A. Giwercman, G. Daugaard, M. Rorth, J. H. Petersen, N. E. Skakkebaek, S. W. Hansen, and H. von der Maase Effect of Graded Testicular Doses of Radiotherapy in Patients Treated for Carcinoma-In-Situ in the Testis J. Clin. Oncol., March 15, 2002; 20(6): 1537 - 1543. [Abstract] [Full Text] [PDF]

				P. M. Petersen, A. Giwercman, S. W. Hansen, J. G. Berthelsen, G. Daugaard, M. Rorth, and N. E. Skakkebak Impaired Testicular Function in Patients With Carcinoma-In-Situ of the Testis J. Clin. Oncol., January 1, 1999; 17(1): 173 - 173. [Abstract] [Full Text] [PDF]

				P. M. Petersen, A.-M. Andersson, M. Rørth, G. Daugaard, and N. E. Skakkebæk Undetectable Inhibin B Serum Levels in Men after Testicular Irradiation J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 213 - 215. [Abstract] [Full Text]

				H. Roelofs, R. J. H. L. M. van Gurp, J. W. Oosterhuis, and L. H. J. Looijenga Detection of Human Endogenous Retrovirus Type K-Specific Transcripts in Testicular Parenchyma and Testicular Germ Cell Tumors of Adolescents and Adults : Clinical and Biological Implications Am. J. Pathol., October 1, 1998; 153(4): 1277 - 1282. [Abstract] [Full Text] [PDF]

				S.-C. J. Yeung, A. C. Chiu, R. Vassilopoulou-Sellin, and R. F. Gagel The Endocrine Effects of Nonhormonal Antineoplastic Therapy Endocr. Rev., April 1, 1998; 19(2): 144 - 172. [Abstract] [Full Text]